Early studies using either patient ICC samples (4) or mouse models (5) demonstrated that oncogenic mutations in Kras (typically KrasG12D) and loss-of-function mutations in Trp53 cooperate to initiate tumor formation. Here, KRAS is linked to neoplasm.